Kairos Pharma (KAPA) Liabilities and Shareholders Equity (2023 - 2025)

Kairos Pharma (KAPA) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $6.5 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 13.38% year-over-year to $6.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $26.9 million (up 149.89% YoY) and the FY2025 annual result came in at $6.5 million, up 13.38% from the prior year.
• Liabilities and Shareholders Equity declined to $6.5 million in Q4 2025, from $6.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $7.9 million in Q1 2025 to a low of $965000.0 in Q4 2023.
• A 3-year average of $5.5 million and a median of $6.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity jumped 497.72% — and 2025, when it increased 13.38%.
• Tracing KAPA's Liabilities and Shareholders Equity over 3 years: stood at $965000.0 in 2023, then jumped by 497.72% to $5.8 million in 2024, then increased by 13.38% to $6.5 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $6.5 million (Q4 2025), $6.7 million (Q2 2025), and $7.9 million (Q1 2025), per Business Quant data.